Total
0
Shares
MGC Pharmaceuticals (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) is officially dual listed after beginning trade on the London Stock Exchange (LSE)
  • The healthcare company began trading on the LSE after successfully raising £6.5 million (roughly A$11.6 million)
  • The money was procured via an oversubscribed placement to a number of U.K. based investors
  • MGC listed on the LSE under the ticker code MXC and with an initial market capitalisation of around £33.7 million (about A$60.2 million)
  • Following its acceptance, the company has also become the first medicinal cannabis company to list on the LSE
  • MXC's shares on the ASX are trading for 4.1 cents, up 13.9 per cent

MGC Pharmaceuticals (MXC) is now officially a dual-lister, after beginning trade on the London Stock Exchange (LSE).

The medical cannabis company began trading on the LSE on February 9 after successfully raising £6.5 million (roughly A$11.6 million).

MGC listed on the stock exchange under its same ASX ticker code - MXC - with shares initially worth 1.475 pence per share.

That gave the healthcare stock an initial market capitalisation of around £33.7 million (about A$60.2 million).

Commenting on the company's move into the U.K. market, MGC Pharmaceuticals Managing Director Roby Zomer said it was hugely significant.

"We are proud to make history as the first medical cannabis company on this historic exchange," he said.

"I would like to thank the MGC Pharma team and the advisors for all their hard work to make this happen," he added.

MXC raised the £6.5 million via an oversubscribed placement to a number of U.K. based investors.

The company plans to use the cash to fund its priority clinical research trials, distribution network expansion and construct its planned manufacturing facilities in Malta.

MGC Pharmaceuticals share price on the ASX has jumped up 13.9 per cent following today's LSE listing announcement.

Company shares ended the day trading at 4.1 cents each.

MXC by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.